© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

Cambridge Biotech Company Asks Feds For OK On New Ebola Drug

A Cambridge-based biotech company is seeking approval from federal regulators to use its experimental medication on patients brought to the United States for treatment after being infected in West Africa’s deadly Ebola outbreak.

Sarepta Therapeutics says if given approval, the firm will, within a few months, have enough of the injectible drug — AVI-75370 — for up to 125 patients.

The drug aims to stop the virus from replicating, allowing the body to fight it off.

So far, Sarepta’s treatment has only been tested on monkeys, with a 60 to 80 percent success rate; it has never been tried on a human infected with the virus.

Chris Garabedian, the company’s CEO, told WBUR that this rate is promising.

“Non-human primates that don’t get the drug, 100 percent of them die in eight to 10 days,” Garabedian said in an interview. “The fact that we can get 60 to 80 percent surviving with basically a 14-day course of the drug is quite remarkable.”

There is no cure or vaccine for Ebola, and researchers have struggled to find an adequate treatment due to Ebola’s rapid pace of infection. The virus immediately attacks and replicates so quickly that when symptoms appear, it leaves little time to treat patients.

Sarepta Therapeutics began working on Ebola treatment in 2010, but due to federal budgetary cuts the testing was halted. But Garabedian is hopeful that the recent outbreak will lead to more funding.

According to the World Health Organization, the recent Ebola outbreak has killed at least 932 people and infected around 1,700 people in Guinea, Sierra Leone, Liberia and Nigeria. Before this year, 1,700 Ebola-related deaths were recorded since the virus was first identified in 1976.

More than 200 new cases were reported last week alone.

Click the player above to listen to the full interview with CEO Garabedian.

Related:

Copyright 2014 WBUR

Bob Oakes and Paige Sutherland

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content